SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Mar. 31, 2025	Dec. 31, 2024
BioCorRx Pharmaceuticals, Inc [Member]
Description of purchased certain assets and assumed certain liabilities		The upfront purchase price was $400,000 to be paid via Seller’s retention, until such amounts equal $400,000 of fifty percent (50%) of the Net Sales (as defined in the APA) of Lucemyra and fifty percent (50%) of the Net Distributable Profits of the generic version of Lucemyra
Description of purchase agreement		the Company, as part of the consideration paid to the Seller for the purchase of the assets, agreed to issue five hundred thousand (500,000) shares of the Company’s Common Stock and to issue a warrant to the Seller for the purchase of five hundred thousand (500,000) shares of Common Stock, which is exercisable for two years and has an exercise price of $1.00 per share
Subsequent Event [Member]
Share issued for services	191,522
Description of exchange agreements	the Company entered into two exchange agreements whereby the parties agreed to exchange the total of $765,885 owed by the Company for 1,874,079 shares of restricted Common Stock
Promissory note valued	$ 68,723
Subsequent Event [Member] \| Warrants [Member]
Common stock shares issued	234,482